Reported relationships
Latest disclosed role at each company.
No relationships currently tracked through insider filings.
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
No balances currently tracked through insider filings.
Past disclosures · reporting ended (1)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
EyePoint, Inc.
Report date March 30, 2024 · Filed April 02, 2024
Section 16 reporting ended · disclosed 2024-04-02. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 67,080 |
Ending reported balance
After 2024-03-30 transaction · row 6
6 source rows · reconciled sequenceRow 1 · 2024-03-30 · Exercise / conversion · Acquired 5,834 · Balance 48,056 Row 2 · 2024-03-30 · Exercise / conversion · Acquired 30,570 · Balance 78,626 Row 3 · 2024-03-30 · Exercise / conversion · Acquired 14,000 · Balance 92,626 Row 4 · 2024-03-30 · Tax withholding · Disposed 15,493 · Balance 77,133 F1: No shares were sold - these shares were withheld by the issuer to satisfy tax withholding requirements in connection with the Reporting Person's exercise of his withholding right following the vesting of the restricted stock units Row 5 · 2024-03-30 · Tax withholding · Disposed 2,957 · Balance 74,176 F1: No shares were sold - these shares were withheld by the issuer to satisfy tax withholding requirements in connection with the Reporting Person's exercise of his withholding right following the vesting of the restricted stock units Row 6 · 2024-03-30 · Tax withholding · Disposed 7,096 · Balance 67,080 F1: No shares were sold - these shares were withheld by the issuer to satisfy tax withholding requirements in connection with the Reporting Person's exercise of his withholding right following the vesting of the restricted stock units |
| Restricted Stock UnitsSEC Table II · derivative / convertible security · Conversion / exercise price $0.00 | Direct | 0 |
Reported balance
After 2024-03-30 transaction · row 7
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 7 · 2024-03-30 · Exercise / conversion · Disposed 30,570 · Balance 0 F2: The restricted stock units will vest in three ratable annual installments beginning January 6, 2024. |
| Restricted Stock UnitsSEC Table II · derivative / convertible security · Conversion / exercise price $0.00 | Direct | 0 |
Reported balance
After 2024-03-30 transaction · row 8
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 8 · 2024-03-30 · Exercise / conversion · Disposed 5,834 · Balance 0 F3: The restricted stock units will vest in three ratable annual installments beginning February 9, 2023. |
| Restricted Stock UnitsSEC Table II · derivative / convertible security · Conversion / exercise price $0.00 | Direct | 0 |
Reported balance
After 2024-03-30 transaction · row 9
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 9 · 2024-03-30 · Exercise / conversion · Disposed 14,000 · Balance 0 F4: The restricted stock units will vest in three ratable annual installments beginning January 5, 2025. |
Filing footnotes · ownership attribution and instrument terms
F1: No shares were sold - these shares were withheld by the issuer to satisfy tax withholding requirements in connection with the Reporting Person's exercise of his withholding right following the vesting of the restricted stock units
F2: The restricted stock units will vest in three ratable annual installments beginning January 6, 2024.
F3: The restricted stock units will vest in three ratable annual installments beginning February 9, 2023.
F4: The restricted stock units will vest in three ratable annual installments beginning January 5, 2025.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| October 12, 2018 Filed Oct 16, 2018 20:00 UTC | EyePoint, Inc. EYPT · Entity 5702 | Tax withholdingCommon Stock | 2,455 | $3.23 | $7,929.65 |
DisclosureSEC source: 0000899243-18-026781 · doc4.xml · nonDerivative · entry 2 Paggiarino Dario A. · CIK 0001574261 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 29,600 F2 · shares: No shares were sold - these shares were withheld by the issuer to satisfy tax withholding requirements in connection with the Reporting Person's exercise of his withholding right following the vesting of the performance stock units. Read SEC document |
| October 12, 2018 Filed Oct 16, 2018 20:00 UTC | EyePoint, Inc. EYPT · Entity 5702 | GrantCommon Stock | 16,667 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-18-026781 · doc4.xml · nonDerivative · entry 1 Paggiarino Dario A. · CIK 0001574261 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 32,055 F1 · shares: On October 12, 2018 (the "FDA Approval Date"), the U.S. Food and Drug Administration approved EyePoint Pharmaceutical Inc.'s (the "Company") new drug application for YUTIQ for the treatment of chronic non-infectious uveitis affecting the posterior segment of the eye. As a result, 8,334 shares representing a previously granted performance stock unit award vested on that date. An additional 8,333 shares from this award will vest on the first anniversary of the FDA Approval Date, subject to the Reporting Person's continued employment with the Company through the applicable vesting date. Read SEC document |
| June 27, 2018 Filed Jun 29, 2018 20:00 UTC | EyePoint, Inc. EYPT · Entity 5702 | Exercise / conversionRestricted Stock Units · Derivative | 10,000 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-18-018710 · doc4.xml · derivative · entry 3 Paggiarino Dario A. · CIK 0001574261 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,000 Underlying: Common Stock · 10,000 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Restricted stock units convert into common stock on a one-for-one basis. F2 · derivative.exercise_date: On June 27, 2017, the reporting person was granted 30,000 restricted stock units, vesting in three equal annual installments beginning on the first anniversary of the grant date. F2 · derivative.expiration_date: On June 27, 2017, the reporting person was granted 30,000 restricted stock units, vesting in three equal annual installments beginning on the first anniversary of the grant date. Read SEC document |
| June 27, 2018 Filed Jun 29, 2018 20:00 UTC | EyePoint, Inc. EYPT · Entity 5702 | Tax withholdingCommon Stock | 2,945 | $1.86 | $5,477.70 |
DisclosureSEC source: 0000899243-18-018710 · doc4.xml · nonDerivative · entry 2 Paggiarino Dario A. · CIK 0001574261 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,388 F3 · shares: No shares were sold - these shares were withheld by the issuer to satisfy tax withholding requirements in connection with the insider's exercise of his withholding right following the vesting of the restricted stock units. Read SEC document |
| June 27, 2018 Filed Jun 29, 2018 20:00 UTC | EyePoint, Inc. EYPT · Entity 5702 | Exercise / conversionCommon Stock | 10,000 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000899243-18-018710 · doc4.xml · nonDerivative · entry 1 Paggiarino Dario A. · CIK 0001574261 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 18,333 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Restricted stock units convert into common stock on a one-for-one basis. Read SEC document |
| June 14, 2018 Filed Jun 18, 2018 20:11 UTC | EyePoint, Inc. EYPT · Entity 5702 | GrantStock Option (right to buy) · Derivative | 170,500 | $0.00 Strike: $2.04 | $0.00 |
DisclosureSEC source: 0000899243-18-016986 · doc4.xml · derivative · entry 2 Paggiarino Dario A. · CIK 0001574261 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 170,500 Underlying: Common Stock · 170,500 shares Expires 2028-06-14 F3 · derivative.exercise_date: The option to purchase will vest and become exercisable in three equal annual installments beginning June 14, 2019. Read SEC document |
| June 14, 2018 Filed Jun 18, 2018 20:11 UTC | EyePoint, Inc. EYPT · Entity 5702 | GrantRestricted Stock Units · Derivative | 42,600 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-18-016986 · doc4.xml · derivative · entry 1 Paggiarino Dario A. · CIK 0001574261 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 42,600 Underlying: Common Stock · 42,600 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of the Company's common stock. F2 · derivative.exercise_date: The restricted stock units will vest in three equal annual installments beginning June 14, 2019. Vested shares will be delivered to the reporting person within 30 days following each respective vesting date. F2 · derivative.expiration_date: The restricted stock units will vest in three equal annual installments beginning June 14, 2019. Vested shares will be delivered to the reporting person within 30 days following each respective vesting date. Read SEC document |
| March 19, 2018 Filed Mar 21, 2018 20:00 UTC | EyePoint, Inc. PSDV · Entity 5702 | GrantCommon stock | 8,333 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-18-008245 · doc4.xml · nonDerivative · entry 1 Paggiarino Dario A. · CIK 0001574261 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,333 F1 · shares: On March 19, 2018 (the "NDA Acceptance Date"), the U.S. Food and Drug Administration ("FDA") accepted pSivida Corp.'s (the "Company") new drug application for Durasert 3-year treatment for posterior segment uveitis. As a result, 4,166 shares representing a previously granted performance stock unit award vested on that date. An additional 4,167 shares from this award will vest on the first anniversary of the NDA Acceptance Date, subject to the Reporting Person's continued employment with the Company through the applicable vesting date. Read SEC document |
| June 27, 2017 Filed Jun 29, 2017 20:03 UTC | EyePoint, Inc. PSDV · Entity 5702 | GrantStock Option (right to buy) · Derivative | 60,000 | $0.00 Strike: $1.77 | $0.00 |
DisclosureSEC source: 0000899243-17-017520 · doc4.xml · derivative · entry 2 Paggiarino Dario A. · CIK 0001574261 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 60,000 Underlying: Common Stock · 60,000 shares Expires 2027-06-27 F3 · derivative.exercise_date: The option to purchase will vest and become exercisable in three equal annual installments beginning June 27, 2018. Read SEC document |
| June 27, 2017 Filed Jun 29, 2017 20:03 UTC | EyePoint, Inc. PSDV · Entity 5702 | GrantRestricted Stock Units · Derivative | 30,000 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-17-017520 · doc4.xml · derivative · entry 1 Paggiarino Dario A. · CIK 0001574261 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 30,000 Underlying: Common Stock · 30,000 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of the Company's common stock. F2 · derivative.exercise_date: The restricted stock units will vest in three equal annual installments beginning June 27, 2018. Vested shares will be delivered to the reporting person within 30 days following each respective vesting date. F2 · derivative.expiration_date: The restricted stock units will vest in three equal annual installments beginning June 27, 2018. Vested shares will be delivered to the reporting person within 30 days following each respective vesting date. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.